U.S. Influenza Vaccines Market, by Vaccine Type, by Virus Type and by Age Group - Trends, and Forecast till 2025

Influenza is an infection caused by influenza virus and is commonly known as flu. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. According to the World health Organization (WHO), 2017, Influenza virus is transmitted primarily by respiratory secretions or droplets of the infected person. It has an annual global attack rate of 5–10% in adults and 20–30% in children. Influenza vaccines are available with a wide range of options for different age groups i.e. children aged 6 months and above and adults aged 65 and above. According to the American Public Health Association, 2015, Influenza vaccines confer protection with 60–90% efficacy among the recipients, thus increasing the adoption rate of the vaccines.

Ask for SAPLE copy of this business report : https://www.coherentmarketinsights.com/insight/request-sample/1127

The U.S. influenza vaccines market was valued at US$ 2.1 billion in 2016 and is expected to witness a CAGR of 15.9% over the forecast period (2017–2025).

Rising incidence of pandemic events and increasing awareness, leading to improved pandemic preparedness is expected to boost the market growth

Rising pandemic events is mainly attributed to genetic diversity of influenza viruses with varying patterns and severity. Risk of the onset of a novel pandemic strain has resulted in rise in research and development for production of efficacious influenza vaccines. Pandemic planning is expected to reduce transmission of pandemic virus, which can eventually decrease hospitalizations and deaths, thus minimizing the social and economic impact of pandemic events. According to the World Health Organization, in 2015, around 233 million outpatient visits, 5.2 million hospital admissions, and 7.4 million deaths are expected to manifest if a pandemic event were to occur, globally. Also, the Centers for Medicare & Medicaid Services (CMS) provides reimbursement covering 100% of the costs of one seasonal influenza virus vaccinations per influenza season, and it also covers additional seasonal influenza virus vaccinations.

Ask for Customization : https://www.coherentmarketinsights.com/insight/request-customization/1127

Government initiatives to tackle such events is a major factor propelling growth of the U.S. influenza vaccine market

The government agencies in the U.S. are focusing on collaborations in order to increase the supply of influenza vaccines. For instance, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza vaccines, as a part of inter-agency government effort in the U.S.

In August 2017, Sanofi Pasteur acquired Protein Sciences Corporation, thus adding Flublok product to its portfolio — the only FDA approved recombinant protein-based influenza vaccine. With the acquisition, Sanofi expanded its influenza vaccine portfolio and its presence in the global respiratory vaccines market by exploring the non-egg-based manufacturing technologies.

The key players operating in the influenza vaccines market include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com
Visit Our New Website : https://www.coherentwire.com

This release was published on openPR.